Wanda Keagle
Family · Cookeville, TNNPI 1740565282
Payments from drug & device makers
Across 234 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$821
- GSK$658
- Novo Nordisk$583
- AstraZeneca$583
- Pfizer$211
- Amgen$178
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,23999%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $821 |
| GSK | 35 | $658 |
| Novo Nordisk | 35 | $583 |
| AstraZeneca | 30 | $583 |
| Pfizer | 11 | $211 |
| Amgen | 9 | $178 |
| Astellas Pharma US Inc | 9 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $155 |
| Lilly USA, LLC | 9 | $133 |
| Phathom Pharmaceuticals, Inc. | 8 | $93 |
| Corcept Therapeutics | 3 | $72 |
| Cipher Pharmaceuticals US LLC | 1 | $65 |
| Amarin Pharma, Inc. | 4 | $62 |
| Boehringer Ingelheim | 3 | $59 |
| Optinose US, Inc. | 2 | $54 |
| Evoke Pharma, Inc. | 3 | $46 |
| Bayer | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Antares Pharma, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Shield Therapeutics Inc | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| Nevro Corp. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Intra-sana Laboratories | 1 | $20 |
| Mannkind Corporation | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Heartflow, Inc. | 1 | $19 |
| Abbott | 1 | $17 |
How this compares
$4,285 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 268 | $286,087 |
| EliquisApixaban | 144 | $140,970 |
| MounjaroTirzepatide | 89 | $93,225 |
| TrulicityDulaglutide | 48 | $52,792 |
| JardianceEmpagliflozin | 46 | $51,006 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $50,166 |
| XareltoRivaroxaban | 49 | $47,949 |
| FarxigaDapagliflozin Propanediol | 34 | $40,010 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $33,053 |
| LinzessLinaclotide | 36 | $28,632 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 34 | $23,940 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $22,848 |
| JanuviaSitagliptin Phosphate | 29 | $21,231 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $18,937 |
| Bydureon BciseExenatide Microspheres | 19 | $16,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $583 | $286,087268 claims |
| PfizerEliquis, Premarin | $211 | $147,674155 claims |
| Lilly USA, LLCMounjaro, Trulicity | $133 | $146,017137 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Tradjenta | $59 | $92,849104 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $658 | $90,402113 claims |
| AstraZenecaFarxiga, Symbicort | $583 | $48,59161 claims |
| Johnson & JohnsonXarelto | $24 | $47,94949 claims |
| AbbVieLinzess | $821 | $28,63236 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $26 | $8,88011 claims |
| Astellas Pharma US IncMyrbetriq | $157 | $8,73314 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $155 | $6,06711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.
Other family in Cookeville
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.